Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Treatment of Haemophilia a (HA) Patients with Inhibitors: Immune Tolerance Induction with a Single Factor VIII/Von Willebrand Factor Concentrate in an Observational Immune Tolerance Induction Study (ObsITI)

C. Escuriola Ettingshausen, Erik Berntorp, MD PhD, Yesim Dargaud, MD PhD, Zeynep Gutowski, PhD, Claude Negrier, Anna Pavlova, MD PhD, Johannes Oldenburg

Blood (2018) 132 (Supplement 1): 2482.

https://doi.org/10.1182/blood-2018-99-114408

Published: 2018

Journal Articles

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Blood (2018) 132 (Supplement 1): 2465.

https://doi.org/10.1182/blood-2018-99-113996

Published: 2018

Journal Articles

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

Luciano Baronciani, PhD, Flora Peyvandi, MD PhD, Anne Goodeve, PhD, Reinhard Schneppenheim, MDPhD, Zahra Badiee, Mohammad-Reza Baghaipour, Javier Battle, Erik Berntorp, MD PhD, Imre Bodó, MD PhD, Ulrich Budde, MD, Andrea Cairo, PhD, Giancarlo Castaman, Laura Crookes, Jeroen C.J. Eikenboom, MD, Peyman Eshghi, MD, Cosimo Ettorre, MD, Jenny Goudemand, MD PhD, Wolf Hassenpflug, Charles Richard Morris Hay, MDFRCP,FRCPath, Hamid Hoorfar, MD, Mehran Karimi, MD, Bijan Keikhaei, Riitta Lassila, MD PR, Frank W.G. Leebeek, MD PhD, Maria Fernanda Lopez Fernandez, Pier Mannuccio Mannucci, MD, Maria Gabriella Mazzucconi, MD, Massimo Morfini, MD, Nikolas Nikšić, Johannes Oldenburg, Florian Oyen, Rafael Parra Lòpez, Ian Peake, PhD, Gholamreza Toogeh, Alberto Tosetto, Marc Trossaert, Sayed Omid Reza Zekavat, MD, Eva M.K. Zetterberg, MD PhD, Augusto B Federici, MD

Blood (2018) 132 (Supplement 1): 1184.

https://doi.org/10.1182/blood-2018-99-114702

Published: 2018

Journal Articles

Renal Status and Hematuria in Older Patients with Hemophilia

Pal André Holme, PhDMD, Robert Campbell Tait, MD, Christophe Combescure, PhD, Erik Berntorp, MD PhD, Annarita Tagliaferri, Peter Staritz, MD, Roger E.G. Schutgens, MD PhD, Robert Klamroth, Natascha Marquardt, Stephan Rauchensteiner, Philippe De Moerloose, MD PhD

Blood (2015) 126 (23): 2290.

https://doi.org/10.1182/blood.V126.23.2290.2290

Published: 2015

Journal Articles

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Gerald Spotts, PhD, Steven W. Pipe, MD, Erik Berntorp, MD PhD, Peter W. Collins, MD, Victor S. Blanchette, MD FRCPC, Kathelijn Fischer, MD PhD MSC, MyungShin Oh, Leonard A. Valentino, MD FAAP

Blood (2014) 124 (21): 689.

https://doi.org/10.1182/blood.V124.21.689.689

Published: 2014

Journal Articles

Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients.

Pablo Rendo, MD, Erik Berntorp, MD, PhD, David M. Keeling, MD, Michael Makris, MD, Cedric R. Hermans, MD., PhD., Ereline Pauline Mauser-Bunschosten, Roberto Musso, Annarita Tagliaferri, Carl Kollmer, James Baumann, Robert Charnigo

Blood (2010) 116 (21): 3664.

https://doi.org/10.1182/blood.V116.21.3664.3664

Published: 2010

Journal Articles

Regular Replacement Therapy as Prophylaxis In Severe Forms of Von Willebrand Disease: Initial Results From the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group

Erik Berntorp, MD, PhD, Thomas C. Abshire, MD, Augusto B. Federici, MD

Blood (2010) 116 (21): 236.

https://doi.org/10.1182/blood.V116.21.236.236

Published: 2010

Journal Articles

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Jan Astermark, MD, PhD, John Schwarz, MA, Sharyne M. Donfield, PhD, Donna M. DiMichele, MD, Bruce M. Ewenstein, MD, PhD, Edward D. Gomperts, MD, George W. Nelson, PhD, Johannes Oldenburg, MD, PhD, Amy D. Shapiro, MD, Gerald Spotts, PhD, Cheryl A. Winkler, PhD, Erik Berntorp, MD, PhD

Blood (2009) 114 (22): 217.

https://doi.org/10.1182/blood.V114.22.217.217

Published: 2009

Journal Articles

Health-Economic Analysis of Alternative Bypassing Agents in Haemophilia Complicated by an Inhibitor - the FEIBA® NovoSeven® Comparative Study (FENOC).

Katarina Steen Carlsson, PhD, Jan Astermark, PhD, MD, Sharyne M. Donfield, PhD, Erik Berntorp, MD

Blood (2006) 108 (11): 457.

https://doi.org/10.1182/blood.V108.11.457.457

Published: 2006

Journal Articles

Polymorphisms in the Promoter Region of the IL-10 Gene Is Associated with Inhibitor Development in Hemophilia A.

Jan Astermark, MD, PhD, Johannes Oldenburg, MD, PhD, Anna Pavlova, Erik Berntorp, MD, PhD, Ann-Kari Lefvert, MD, PhD, MIBS Study Group

Blood (2005) 106 (11): 212.

https://doi.org/10.1182/blood.V106.11.212.212

Published: 2005

Journal Articles

The FEIBA ® NovoSeven ® Comparative Study (FENOC)—A Randomized Evaluation of By-Passing Agents in Hemophilia Complicated by Inhibitors.

Erik Berntorp, MD, PhD, Sharyne Donfield, PhD, Jennifer Waters, JD, Eva Mattson, RN, Donna DiMichele, MD, Alessandro Gringeri, MD, PhD, Jan Astermark, MD, PhD

Blood (2005) 106 (11): 324.

https://doi.org/10.1182/blood.V106.11.324.324

Published: 2005

Journal Articles

Activation of the Coagulation System Should Be Considered in the Initial Phase of Chemotherapy in Acute Myeloid Leukemia.

Jan Astermark, MD PhD, Karin Strandberg, MD PhD, Bengt Sallerfors, MD PhD, Johan Stenflo, MD PhD, Erik Berntorp, MD PhD

Blood (2004) 104 (11): 1039.

https://doi.org/10.1182/blood.V104.11.1039.1039

Published: 2004

NARROW

Treatment of Haemophilia a (HA) Patients with Inhibitors: Immune Tolerance Induction with a Single Factor VIII/Von Willebrand Factor Concentrate in an Observational Immune Tolerance Induction Study (ObsITI)

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

Renal Status and Hematuria in Older Patients with Hemophilia

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients.

Regular Replacement Therapy as Prophylaxis In Severe Forms of Von Willebrand Disease: Initial Results From the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group

Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Health-Economic Analysis of Alternative Bypassing Agents in Haemophilia Complicated by an Inhibitor - the FEIBA® NovoSeven® Comparative Study (FENOC).

Polymorphisms in the Promoter Region of the IL-10 Gene Is Associated with Inhibitor Development in Hemophilia A.

The FEIBA ® NovoSeven ® Comparative Study (FENOC)—A Randomized Evaluation of By-Passing Agents in Hemophilia Complicated by Inhibitors.

Activation of the Coagulation System Should Be Considered in the Initial Phase of Chemotherapy in Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only